For overall safety, see our peptide safety guide and getting started with peptides
Saiki, A
Keywords: Triple agonists, Triagonists, Glucagon-like peptide 1, Gastric inhibitory polypeptide, Glucagon, Obesity, Weight loss, Retatrutide, Co-agonist INTRODUCTION Obesity is a chronic, neurometabolic disease, which has now reached pandemic dimensions with continuing increasing numbers of affected individuals worldwide
Current clinical trial data from the SURPASS programmethe pivotal phase 3 trials that led to Mounjaro's approvaldo not list insomnia as a common or frequently reported adverse effect
Who Should Avoid BPC-157
References Scientific Review Scientific Contributor and Reviewer Reviewed for scientific accuracy, 14 June 2026 Lyophilised powder: store at -20 C or below, away from light and moisture